Prostate cancer (PCa) is the most frequently occurring male cancer in Belgium. After treatment with surgery and/or radiotherapy, almost half of the patients suffer from a tumor recurrence, often diagnosed by an increase in serum tumor marker Prostate Specific Antigen (PSA) within the first few years after primary treatment. However, for salvage therapy to be successful, precise localization of metastases is necessary to determine the most appropriate treatment. In so-called oligo-metastatic disease targeted therapy may still be curative and prevent the disease from spreading to distant locations. Therefore it is of paramount importance to have an accurate tool of medical imaging to localize all possible locations to be treated. Recently, prostate specific membrane antigen (PSMA) has gained interest for PCa-specific imaging. Due to overexpression of PSMA in both primary and metastatic PCa, radiotracers targeting this protein have shown an increased selectivity and sensitivity compared to conventional imaging. The main objective of this phase 3 trial is to determine the position of \[18F\]PSMA-11 PET/CT within the field of available radiotracers for diagnosis of prostate cancer. For this, the diagnostic performances of \[18F\]PSMA-11 will be compared to those of the current state-of-the-art radiotracer \[68Ga\]PSMA-11.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Enrollment
96
\[18F\]PSMA-11 PET/CT
\[68Ga\]PSMA-11 PET/CT
Ghent University Hospital
Ghent, East Flanders, Belgium
Evaluation of the non-inferiority of [18F]PSMA-11 compared to [68Ga]PSMA-11 with respect to the number of positive PET scans. Hereby, a positive PET scan is defined as a scan showing at least one suspected lesion.
The non-inferiority of \[18F\]PSMA-11 will be investigated based on a Tango's score two-sided 95% confidence interval (CI) for a difference of proportions of positive scans of \[18F\]PSMA-11 compared to \[68Ga\]PSMA-11 with matched pairs. Non-inferiority will be concluded if the lower limit of this CI is larger than 0.10 (non-inferiority limit).
Time frame: 0 to 100 minutes post injection for both [18F]PSMA-11 and [68Ga]PSMA-11
Evaluation of the superiority of [18F]PSMA-11 compared to [68Ga]PSMA-11 with respect to the number of positive PET scans. Hereby, a positive PET scan is defined as a scan showing at least one suspected lesion.
Superiority of \[18F\]PSMA-11 compared to \[68Ga\]PSMA-11 with respect to the number of positive PET scans will be statistically assessed by applying a McNemar's test on the proportions of positive PET scans in each group. Hereby, superiority is defined as a difference of minimum 10% in the proportions of positive PET scans (\[18F\]PSMA-11 \> \[68Ga\]PSMA-11).
Time frame: 0 to 100 minutes post injection for both [18F]PSMA-11 and [68Ga]PSMA-11
Evaluation of the superiority of [18F]PSMA-11 compared to [68Ga]PSMA-11 with respect to the total number of suspected prostate cancer lesions in corresponding ([68Ga]PSMA-11 vs [18F]PSMA-11) scans.
The McNemar-Bowker test of symmetry of k X k contingency tables will be applied to investigate differences between \[18F\]PSMA-11 and \[68Ga\]PSMA-11 scans. Hereby, the superiority is defined as a difference of minimum 10% (\[18F\]PSMA-11 \> \[68Ga\]PSMA-11).
Time frame: 0 to 100 minutes post injection for both [18F]PSMA-11 and [68Ga]PSMA-11
Evaluation of the superiority of [18F]PSMA-11 compared to [68Ga]PSMA-11 with respect to the scoring of corresponding ([68Ga]PSMA-11 vs [18F]PSMA-11) suspected lesions.
The McNemar-Bowker test of symmetry of k X k contingency tables will be applied to investigate differences between \[18F\]PSMA-11 and \[68Ga\]PSMA-11 scans. Hereby, the superiority is defined as a difference of minimum 10% (\[18F\]PSMA-11 \> \[68Ga\]PSMA-11).
Time frame: 0 to 100 minutes post injection for both [18F]PSMA-11 and [68Ga]PSMA-11
Descriptive evaluation of [18F]PSMA-11 compared to [68Ga]PSMA
This endpoint will be examined in the total group of patients, as well as in a subgroup of patients with a specific disease stage including primary diagnosis, castrate sensitive biochemical recurrence, and castrate resistant biochemical recurrence. Additionally, within these subgroups, a further subdivision can be made on the basis of a specific location of the suspected lesions, PSA values, PSA doubling times and metastatic disease burden).
Time frame: 0 to 100 minutes post injection for both [18F]PSMA-11 and [68Ga]PSMA-11
Evaluation of the diagnostic specificity of [18F]PSMA-11 compared to [68Ga]PSMA-11
This endpoint will be evaluated in a descriptive way, more specifically by a description of the number of positive scans (and/or positive lesions) that can be confirmed via an anatomopathological diagnosis, changes in PSA concentration or via MRI, and by comparison of these numbers between \[18F\]PSMA-11 and \[68Ga\]PSMA-11.
Time frame: 0 to 180 days post [18F]PSMA-11 and [68Ga]PSMA-11 administration
Evaluation of the safety of [18F]PSMA-11 administration: CTCAE 4.0 criteria
Adverse events will be reported and scored (CTCAE 4.0 criteria) between the first dose administration of trial medication and the last trial related activity. From the time of radiotracer injection till completion of the PET/CT scan (for both \[18F\]PSMA-11 and \[68Ga\]PSMA-11), the site staff will visually observe and actively ask the patient whether or not he has observed any adverse effects. Although \[18F\]PSMA-11 is totally eliminated from the body within 9 hours post injection (= 10 x half-life of 47 ± 5 minutes), AE's occurring up to 24h after the second PET/CT scan will also be handled as such if spontaneously reported by the patient to the investigator.
Time frame: 0 to 24 h post [18F]PSMA-11 and [68Ga]PSMA-11 administration
Assessment of the interobserver variability with regard to the evaluation of the [18F]PSMA-11 and [68Ga]PSMA-11 PET scans
This endpoint will be evaluated by determining a Cohen's kappa value
Time frame: 0 to 100 minutes post injection for both [18F]PSMA-11 and [68Ga]PSMA-11
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.